Short answer
Nkarta, Inc. (NKTX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$33M
- −53.5% YoY · +17.4% QoQ
- EPS (diluted)
- −$0.44
- −46.7% YoY · +20.0% QoQ
Source: XBRL data from the Nkarta, Inc. (NKTX) Q3 2026 10-Q on SEC EDGAR. USD.
Nkarta, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, with no product sales since inception
- Operating margin not applicable, net loss $(33.3) million vs $(21.7) million YoY
- NKX019 R&D spending $11.4 million, up from $4.3 million YoY
- Cash, restricted cash and investments $216.0 million as of September 30, 2026
- Operating cash outflow $78.3 million, up from $67.1 million YoY; funding sufficient for at least 12 months
Risk Factors
- Losses $101.5 million, accumulated deficit $749.8 million as of September 30, 2026
- Cash, restricted cash and investments $216.0 million, additional financing needed for pivotal trials
- FDA-agreed amendments enabled outpatient dosing and re-dosing, increasing safety-monitoring and cumulative-toxicity exposure
- Ntrust-1 and Ntrust-2 enrollment challenges from competition for autoimmune trial sites, investigators and patients
- Miltenyi CliniMACS Plus system and reagents remain sole-source manufacturing inputs, with four-to-six-month reagent expiration windows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nkarta, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.